CORVIDIA

Precision Cardiovascular Therapeutics

The Corvidia Approach

At Corvidia Therapeutics, we are creating precision therapies by using the science of genomics in new ways.

Through random genetic mutation, nature conducts experiments, subtly changing how key proteins work in our bodies and influencing the factors that drive diseases differently in different groups of patients. We study the networks of these genetic variations and how they affect specific diseases in specific patients, allowing us to understand how a personalized drug in complex diseases may behave before we ever begin a clinical trial.  We believe that by leveraging the inner networks of genomics we can develop therapies tailored to patients across a range of complex diseases. Working together, our team of distinguished scientists, experienced drug developers and a successful group of investors are focused on bringing these innovations to patients.

Our Patient Focus

We believe that no two patients are identical in their treatment needs and there are vast number of patients around the world whose needs are presently unmet.

Using our precise approach to study the genetic variations of diseases and the patients they affect, we understand how a personalized drug in these complex diseases may behave before we ever begin a clinical trial. Approximately 2.5 million people worldwide suffer from advanced renal or kidney disease*. The greatest threat to these patients is the risk of cardiovascular events. Inflammation is a key factor that increases the chances of a serious cardiac event in these patients. In addition to an increased risk of heart failure, advanced kidney disease patients who have inflammation often have a significantly decreased quality of life, experiencing anemia, chronic exhaustion, muscle weakness, loss of appetite and depression. Dialysis is the current treatment paradigm for advanced kidney disease. We believe that by applying our understanding of the networks of genetic variation, we can for the first time address the chronic inflammation of advanced kidney disease in a uniquely at-risk population, limiting the systemic effects of this inflammation, thereby improving quality of life while further enhancing current renal care.